Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | First-line axicabtagene ciloleucel in lymphoma

Yago Nieto • 15 Feb 2021
TCT 2021
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel

Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of axicabtagene ciloleucel in the front-line setting for patients with relapsed/refractory non-Hodgkin lymphoma. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Yago Nieto

2:10
High-dose chemotherapy and autoSCT for R/R primary mediastinal large B-cell lymphoma
Yago Nieto • 11 Dec 2023
2:55
AFM13 with cord blood-derived NK-cell therapy in patients with refractory CD30-positive lymphomas
Yago Nieto • 11 Dec 2023
3:32
Phase II study of panobinostat/GemBuMel with autoSCT in high-risk or R/R multiple myeloma
Yago Nieto • 13 Feb 2023
2:33
Phase I/II study of olaparib plus vorinostat/GemBuMel with autoSCT in R/R lymphomas
Yago Nieto • 11 Dec 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals